Despite a fall in the number of people with asthma over the past decade who say that cost has stopped them taking their meds as prescribed, financial hardship still remains a deterrent for 1 in 6 with the condition, suggests research published online in the respiratory medicine journal Thorax.
FDA grants fast track designation for Verastem’s NSCLC therapy
Share this article The FDA designation is intended for the usage of avutometinib along with Amgen’s LUMAKRAS to treat KRAS G12C-mutant metastatic NSCLC patients. Credit: